Automate Your Wheel Strategy on IMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including IMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMAB
- Rev/Share 0.0
- Book/Share 1.0568
- PB 6.336
- Debt/Equity 0.0186
- CurrentRatio 22.3498
- ROIC -0.1121
- MktCap 1257622924.0995
- FreeCF/Share 0.0
- PFCF 0.0
- PE -165.856
- Debt/Assets 0.0176
- DivYield 0
- ROE -0.0355
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Published: July 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8 th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical …
Read More
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
I-Mab Sponsored ADR (IMAB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, IMAB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for IMab (IMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for IMab (IMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
I-Mab to Participate in Leerink Partners Global Healthcare Conference
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab's management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.
Read More
About I-Mab (IMAB)
- IPO Date 2020-01-17
- Website https://www.i-mabbiopharma.com
- Industry Biotechnology
- CEO Xi-Yong Fu
- Employees 32